N‐terminal truncated pyroglutamyl β amyloid peptide Aβpy3‐42 shows a faster aggregation kinetics than the full‐length Aβ1‐42

We tested directly the differences in the aggregation kinetics of three important β amyloid peptides, the full‐length Aβ1‐42, and the two N‐terminal truncated and pyroglutamil modified Aβpy3‐42 and Aβpy11‐42 found in different relative concentrations in the brains in normal aging and in Alzheimer disease. By following the circular dichroism signal and the ThT fluorescence of the solution in phosphate buffer, we found substantially faster aggregation kinetics for Aβpy3‐42. This behavior is due to the particular sequence of this peptide, which is also responsible for the specific oligomeric aggregation states, found by TEM, during the fibrillization process, which are very different from those of Aβ1‐42, more prone to fibril formation. In addition, Aβpy3‐42 is found here to have an inhibitory effect on Aβ1‐42 fibrillogenesis, coherently with its known greater infective power. This is an indication of the important role of this peptide in the aggregation process of β‐peptides in Alzheimer disease. © 2009 Wiley Periodicals, Inc. Biopolymers 91: 861–873, 2009.

[1]  H. Lashuel,et al.  The Ratio of Monomeric to Aggregated Forms of Aβ40 and Aβ42 Is an Important Determinant of Amyloid-β Aggregation, Fibrillogenesis, and Toxicity* , 2008, Journal of Biological Chemistry.

[2]  Hans-Ulrich Demuth,et al.  Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology , 2008, Nature Medicine.

[3]  J. Shine,et al.  Acceleration of Amyloid β-Peptide Aggregation by Physiological Concentrations of Calcium* , 2006, Journal of Biological Chemistry.

[4]  Hans-Ulrich Demuth,et al.  On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). , 2006, Biochemistry.

[5]  J. Danielsson,et al.  15N relaxation study of the amyloid β‐peptide: structural propensities and persistence length , 2006, Magnetic resonance in chemistry : MRC.

[6]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[7]  P. Carey,et al.  Raman crystallography and other biochemical applications of Raman microscopy. , 2006, Annual review of physical chemistry.

[8]  A. Bonvin,et al.  The α‐to‐β Conformational Transition of Alzheimer's Aβ‐(1–42) Peptide in Aqueous Media is Reversible: A Step by Step Conformational Analysis Suggests the Location of β Conformation Seeding , 2006 .

[9]  Paul R. Carey,et al.  Secondary Structure of α-Synuclein Oligomers: Characterization by Raman and Atomic Force Microscopy , 2006 .

[10]  D. Teplow,et al.  Conformational dynamics of amyloid beta-protein assembly probed using intrinsic fluorescence. , 2005, Biochemistry.

[11]  A. Gliozzi,et al.  β-Amyloid Is Different in Normal Aging and in Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[12]  C. Ionescu-Zanetti,et al.  Mechanism of thioflavin T binding to amyloid fibrils. , 2005, Journal of structural biology.

[13]  J. Danielsson,et al.  The Alzheimer β‐peptide shows temperature‐dependent transitions between left‐handed 31‐helix, β‐strand and random coil secondary structures , 2005 .

[14]  Hai Lin,et al.  Amyloid ion channels: a common structural link for protein-misfolding disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Selkoe,et al.  Alzheimer disease: mechanistic understanding predicts novel therapies. , 2004 .

[16]  T. Hoffmann,et al.  Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions , 2004, FEBS letters.

[17]  Clifford J. Woolf,et al.  Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management , 2004, Annals of Internal Medicine.

[18]  N. Maiti,et al.  Raman spectroscopic characterization of secondary structure in natively unfolded proteins: alpha-synuclein. , 2004, Journal of the American Chemical Society.

[19]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[20]  G. Krafft,et al.  In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.

[21]  George Perry,et al.  Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. , 2003, Biochemistry.

[22]  Christopher M Dobson,et al.  The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation , 2002, The EMBO journal.

[23]  M. Franceschi,et al.  Protein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanisms , 2002, Neurobiology of Aging.

[24]  G. Damonte,et al.  Pyroglutamate‐modified amyloid β‐peptides – AβN3(pE) – strongly affect cultured neuron and astrocyte survival , 2002 .

[25]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[26]  M. Nagao,et al.  Aggregation and neurotoxicity of mutant amyloid β (Aβ) peptides with proline replacement: importance of turn formation at positions 22 and 23 , 2002 .

[27]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[28]  Christopher M. Dobson,et al.  Kinetic partitioning of protein folding and aggregation , 2002, Nature Structural Biology.

[29]  M. Kirkitadze,et al.  Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. , 2001, Journal of molecular biology.

[30]  Christopher M. Dobson,et al.  Amyloid fibrils from muscle myoglobin , 2001, Nature.

[31]  B. Ghetti,et al.  Neurobiology: Presenilin-1 mutations in Alzheimer's disease , 2000, Nature.

[32]  W. Surewicz,et al.  Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. , 2000, Biochemistry.

[33]  C. Barrow,et al.  On-line high-performance liquid chromatography/mass spectrometric investigation of amyloid-beta peptide variants found in Alzheimer's disease. , 1999, Rapid communications in mass spectrometry : RCM.

[34]  C. Barrow,et al.  The Aβ 3-Pyroglutamyl and 11-Pyroglutamyl Peptides Found in Senile Plaque Have Greater β-Sheet Forming and Aggregation Propensities in Vitro than Full-Length Aβ† , 1999 .

[35]  C M Dobson,et al.  Designing conditions for in vitro formation of amyloid protofilaments and fibrils. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Y. Ihara,et al.  Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques , 1998, Acta Neuropathologica.

[37]  M. Tabaton,et al.  Heterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains , 1997, FEBS letters.

[38]  T. Iwatsubo,et al.  Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain , 1996, Neuroscience Letters.

[39]  D. Selkoe,et al.  Amyloid β-Protein and the Genetics of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[40]  P. Lantos,et al.  A comparison of beta-amyloid deposition in the medial temporal lobe in sporadic Alzheimer's disease, Down's syndrome and normal elderly brains. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[41]  M. Ball,et al.  Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.

[42]  Peter Davies,et al.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans , 1992, Neurobiology of Aging.

[43]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[44]  N. Sreerama,et al.  Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. , 2000, Analytical biochemistry.